Satyanarayana Ande, PhD, received a $439K, 3-year K22 grant from NCI/NIH for “Role of Id1 in adiposity, energy balance and obesity associated liver tumorigenesis.”

Liver cancer is one of the leading causes of cancer deaths worldwide. Obesity is rapidly emerging as a significant risk factor, and the incidence of obesity is growing at an alarming rate. Although the FDA-approved sorafenib showed initial promise in inhibiting unresectable liver cancers, it is associated with many side effects. Therefore, discovery of more effective drug targets to inhibit liver cancer is needed. A protein called Id1 is highly expressed in human liver cancer samples, but its specific role in cancer initiation and progression is not known. This grant will support Dr. Ande’s studies in highly sophisticated knockout and transgenic mouse models that will uncover the specific role of Id1 in liver tumorigenesis, energy balance, and obesity-associated liver cancer. As a result, Id1 will be tested as a novel drug target to treat not only liver cancer, but also obesity-mediated metabolic disorders and liver disease.

Written by
Allison Brown
View all articles
Written by Allison Brown

About Jagwire

Jagwire is the official source for news and stories from Augusta University and AU Health. Daily updates highlight the many ways students, faculty, staff, researchers and clinicians "bring their A games" in classrooms and clinics on four campuses in Augusta and locations across the state of Georgia. Read on for stories of innovation in education and health care, opportunities at the center of Georgia’s new cybersecurity hub, and experiential learning that blends arts and application, humanities and the health sciences. Have a story to share with Jaguar Nation? Contact the Division of Communications & Marketing.